Literature DB >> 9284774

Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.

F Landoni1, A Maneo, A Colombo, F Placa, R Milani, P Perego, G Favini, L Ferri, C Mangioni.   

Abstract

BACKGROUND: Stage Ib and IIa cervical carcinoma can be cured by radical surgery or radiotherapy. These two procedures are equally effective, but differ in associated morbidity and type of complications. In this prospective randomised trial of radiotherapy versus surgery, our aim was to assess the 5-year survival and the rate and pattern of complications and recurrences associated with each treatment.
METHODS: Between September, 1986, and December, 1991, 469 women with newly diagnosed stage Ib and IIa cervical carcinoma were referred to our institute. 343 eligible patients were randomised: 172 to surgery and 171 to radical radiotherapy. Adjuvant radiotherapy was delivered after surgery for women with surgical stage pT2b or greater, less than 3 mm of safe cervical stroma, cut-through, or positive nodes. The primary outcome measures were 5-year survival and the rate of complications. The analysis of survival and recurrence was by intention to treat and analysis of complications was by treatment delivered.
FINDINGS: 170 patients in the surgery group and 167 in the radiotherapy group were included in the intention-to-treat analysis; scheduled treatment was delivered to 169 and 158 women, respectively, 62 of 114 women with cervical diameters of 4 cm or smaller and 46 of 55 with diameters larger than 4 cm received adjuvant therapy. After a median follow-up of 87 (range 57-120) months, 5-year overall and disease-free survival were identical in the surgery and radiotherapy groups (83% and 74%, respectively, for both groups), 86 women developed recurrent disease: 42 (25%) in the surgery group and 44 (26%) in the radiotherapy group. Significant factors for survival in univariate and multivariate analyses were: cervical diameter, positive lymphangiography, and adeno-carcinomatous histotype. 48 (28%) surgery-group patients had severe morbidity compared with 19 (12%) radiotherapy-group patients (p = 0.0004).
INTERPRETATION: There is no treatment of choice for early-stage cervical carcinoma in terms of overall or disease-free survival. The combination of surgery and radiotherapy has the worst morbidity, especially urological complications. The optimum therapy for each patient should take account of clinical factors such as menopausal status, age, medical illness, histological type, and cervical diameter to yield the best cure with minimum complications.

Entities:  

Mesh:

Year:  1997        PMID: 9284774     DOI: 10.1016/S0140-6736(97)02250-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  314 in total

Review 1.  What is meant by intention to treat analysis? Survey of published randomised controlled trials.

Authors:  S Hollis; F Campbell
Journal:  BMJ       Date:  1999-09-11

Review 2.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

Review 3.  Drug therapy for gynaecological cancer in older women.

Authors:  R E van Rijswijk; J B Vermorken
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

4.  mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Authors:  Alfredo A Molinolo; Christina Marsh; Mohamed El Dinali; Nitin Gangane; Kaitlin Jennison; Stephen Hewitt; Vyomesh Patel; Tanguy Y Seiwert; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2012-03-12       Impact factor: 12.531

5.  Usefulness of lymphoscintigraphy and intraoperative gamma probe detection in the identification of sentinel nodes in cervical cancer.

Authors:  Yong An Chung; Sung Hoon Kim; Hyung Sun Sohn; Soo Kyo Chung; Chae Chun Rhim; Sung Eun Namkoong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-22       Impact factor: 9.236

6.  Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.

Authors:  Masahiro Kagabu; Tadahiro Shoji; Kazuyuki Murakami; Hideo Omi; Tatsuya Honda; Fumiharu Miura; Yoshihito Yokoyama; Hideki Tokunaga; Tadao Takano; Tsuyoshi Ohta; Dai Shimizu; Naoki Sato; Shu Soeda; Takafumi Watanabe; Hidekazu Yamada; Hideki Mizunuma; Nobuo Yaegashi; Satoru Nagase; Toru Tase; Toru Sugiyama
Journal:  Int J Clin Oncol       Date:  2016-01-19       Impact factor: 3.402

7.  Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma.

Authors:  ShanShan Yang; Ying Gao; Jing Sun; Bairong Xia; TianBo Liu; HongXia Zhang; Qi Li; Min Xiao; YunYan Zhang
Journal:  Tumour Biol       Date:  2015-01-21

8.  Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals.

Authors:  M Mangler; N Zech; A Schneider; C Köhler; S Marnitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

9.  A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery.

Authors:  Juan Pu; Shan-shan Qin; Jin-xia Ding; Yan Zhang; Wei-guo Zhu; Chang-hua Yu; Tao Li; Guang-zhou Tao; Fu-zhi Ji; Xi-lei Zhou; Ji-hua Han; Ya-lin Ji; Jun-xia Sun
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-18       Impact factor: 4.553

Review 10.  Image-based brachytherapy for cervical cancer.

Authors:  John A Vargo; Sushil Beriwal
Journal:  World J Clin Oncol       Date:  2014-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.